Opdivo replaces Nivolumab BMS for treatment of lung cancer

Opdivo (nivolumab) is now indicated in the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy, in addition to its original indication in melanoma.

Nivolumab was originally launched for the treatment of NSCLC as Nivolumab BMS, but the manufacturer has now reconciled both indications under the Opdivo brand name. The two brands contain identical presentations of nivolumab and the same dosage regimen is used in both types of cancer.

The discontinuation of Nivolumab BMS will have no impact on patients with lung cancer already being prescribed nivolumab, other than a change in the brand name of their treatment. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic guidance for leg ulcer infection

New antibiotic guidance for leg ulcer infection

NICE has issued guidance on antibiotic choices and...

New insertion site for Nexplanon following safety concerns

New insertion site for Nexplanon following safety concerns

The MHRA has amended its advice relating to the long-acting...

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.

Beta blocker overdose warning for GPs

Beta blocker overdose warning for GPs

The toxicity of a commonly prescribed beta blocker...